Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea
NCT06295562Phase 4Completed
- Sponsor
- China Medical University Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine, oxybutynin, venlafaxine, trazodone hydrochloride prolonged-release tablets in obstructive sleep apnea (OSA), sponsored by China Medical University Hospital. Started Nov 2024; status: completed.
02
Drugs
atomoxetineoxybutyninvenlafaxinetrazodone hydrochloride prolonged-release tablets
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06295562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295562.